SCHEMBL13637361

SCHEMBL13637361

CC(=O)c1ccc2c(c1)c1c3c(ccc1n2CCCN(C)C)C(=O)CC3

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.64
WEE1 P30291 5/20 0.48
CNR2 P34972 2/20 0.48
KDR P35968 4/20 0.41
TEK Q02763 3/20 0.41
CHEK1 O14757 3/20 0.40
SRC P12931 1/20 0.40
MYLK Q15746 1/20 0.40
NPC1 O15118 1/20 0.39
CHRM2 P08172 1/20 0.39
HTR1A P08908 1/20 0.39
CHRM5 P08912 1/20 0.39
ADRA2A P08913 1/20 0.39
DRD2 P14416 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
CHRM3 P20309 1/20 0.39
DRD4 P21917 1/20 0.39
SLC6A2 P23975 1/20 0.39
HRH2 P25021 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16627405 0.97 TP53 (0.62) TP53WEE1CNR2KDRTEK
SCHEMBL16454384 0.94 TP53 (0.66) TP53WEE1CNR2KDRTEK
SCHEMBL16625998 0.91 TP53 (0.62) TP53WEE1CNR2KDRTEK
SCHEMBL16454755 0.90 TP53 (0.60) TP53WEE1CNR2KDRTEK
SCHEMBL15848962 0.90 TP53 (0.60) TP53WEE1CNR2KDRTEK
SCHEMBL12608671 0.89 TP53 (0.51) TP53WEE1CNR2KDRTEK
SCHEMBL16454426 0.89 TP53 (0.58) TP53WEE1CNR2KDRTEK
SCHEMBL16120082 0.89 TP53 (0.67) TP53CNR2KDRTEKNPC1
SCHEMBL16454764 0.88 TP53 (0.61) TP53CNR2KDRTEKNPC1
SCHEMBL16454340 0.88 TP53 (0.59) TP53WEE1CNR2KDRTEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190082845-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON INC (US) 2019-03-21 US disclosed
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2015-12-03 US disclosed
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2015-12-03 US disclosed
US-9108916-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2015-08-18 US disclosed
US-9108916-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2015-08-18 US disclosed
US-20140303224-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, LLC (US) 2014-10-09 US disclosed
US-8765738-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2014-07-01 US disclosed
US-8765738-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2014-07-01 US disclosed
US-8486697-B2 Inducing cell death by inhibiting adaptive heat shock response INCURON, LLC (US) 2013-07-16 US disclosed
EP-2356093-B1 Carbazole compounds and therapeutic uses of the compounds INCURON LLC (RU) 2013-01-09 EP disclosed
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds INCURON, INC. 2011-12-15 US disclosed
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds INCURON, INC. 2011-12-15 US disclosed
WO-2009143290-A2 INDUCING CELL DEATH BY INHIBITING ADAPTIVE HEAT SHOCK RESPONSE CLEVELAND BIOLABS, INC (US) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 TP53 28/4885WEE1 1071/4885CNR2 558/4885
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 TP53 28/4885WEE1 1071/4885CNR2 558/4885
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds MALT1, PAICS, TPMT TP53 33/4885WEE1 1124/4885CNR2 598/4885
US-20140303224-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 TP53 28/4885WEE1 1071/4885CNR2 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.